BeiGene’s outlicensing deal with Novartis underscores how Chinese pharma companies are yards ahead of Indian pharma companies now. Novartis, the Swiss Big Pharma company, has agreed to pay BeiGene $650 million upfront and up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales. This is in exchange…
Read More
Aug’20 saw China’s lifescience sector receive more VC/PE investment than the USA for the second time ever in terms of monthly recorded amounts, with the first instance being in Apr’20. For Aug’20, China reported USD 2024m of venture capital investments, as compared to USD 1531m recorded by the USA. China…
Read More China’s biotech sector continues to blossom as far as fund raising goes. For 4 months in a row, the sector is witnessing increasing amounts of fund raise. While private deals (VC/PE) led the increase in April and May, in June and July, it is public market fund raising that drove…
Read More
We have earlier commented on the sharply accelerated venture capital activity in the biotech sector in China. From around 2-3 deals a month, aggregating maybe USD100m 2-3 years ago, China is now witnessing close to USD1B of venture capital investments in biotech sector on a monthly basis. Keeping company is…
Read More
The Asian Infrastructure Investment Bank (AIIB) is a new multi-lateral lending institution that came about in Jan 2016. AIIB is a Chinese baby. It was proposed by China; it is headquartered in Beijing. A Chinese, Jin Liqun, is the current President of AIIB. Below him, there are 5 vice presidents,…
Read More After the Galvan incident, where China appears to have encroached into Indian territory, and subsequent confirmed deaths of 20 India soldiers, there are lot of calls in India of reducing imports from China. While as a strategy it may have its merits – you don’t want to depend on imports…
2 comments
Earlier this week we wrote how on 2 consecutive months, China’s biotech sector had witnessed more than USD1B of venture capital investment. That chart ignored another source of risk capital – IPOs. China has been producing around 1 biotech IPO a month consistently. These are typically pre-revenue R&D companies, but…
Read More For the second month in a row, China’s biotech companies attracted more than USD1B of venture capital investment. Biotech investments crossed USD1B for the first time in April’20. Hence, May is the second consecutive month where VC/PE investments in biotech have crossed USD1B. In terms of amout invested, China inching…
Read More